Navigation Links
Amylin Pharmaceuticals Reports Third Quarter Financial Results
Date:10/19/2011

showed exenatide, at and above therapeutic levels, did not prolong the corrected QT interval in healthy individuals
  • Announced that the FDA assigned a new Prescription Drug User Fee Act (PDUFA) action date of January 28, 2012 for BYDUREON
  • Presented compelling efficacy and safety data at the European Association for the Study of Diabetes (EASD) Annual Meeting from the DURATION-3 and -4 trials. The studies demonstrated that patients treated with BYDUREON experienced significant improvements in select cardiovascular risk factors, including improvements in composite endpoints related to body weight, abnormal blood pressure and abnormal lipid levels, in comparison to patients who received commonly prescribed diabetes treatments

  • Obesity Program

  • Announced the discontinuation of the pramlintide/metreleptin development program for obesity. The joint decision between Amylin and Takeda Pharmaceuticals Limited was based on a commercial reassessment of the pramlintide/metreleption program. The companies continue to evaluate other assets as potential candidates for the treatment of obesity and related indications under the terms of their existing collaboration agreement

  • Quarter Ended September 30, 2011Net product sales of $155.1 million for the quarter ended September 30, 2011 include $128.1 million for BYETTA® (exenatide) injection and $27.0 million for SYMLIN® (pramlintide acetate) injection. This compares to net product sales of $154.0 million, consisting of $132.4 million for BYETTA and $21.6 million for SYMLIN for the same period in 2010. Revenues under collaborative agreements were $19.9 million for the quarter ended September 30, 2011, and included a $15.0 million milestone payment from Lilly in connection with the launch of BYDUREON in the European Union in July, compared to $2.1 million for the same period in 2010.

    Selling, general and administrative expenses decreased to $63.1 million for the q
    '/>"/>

    SOURCE Amylin Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Amylin Pharmaceuticals to Webcast Third Quarter Results
    2. Amylin Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
    3. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
    4. Amylin Pharmaceuticals to Webcast Second Quarter Results
    5. U.S. District Court Rules in Favor of Lilly in Amylin Litigation
    6. Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order
    7. Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly
    8. Lilly Comments on Court Ruling in Amylin Litigation
    9. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
    10. Lilly Provides Its Perspective in Response to Amylin Lawsuit
    11. Lilly Provides Statement in Response to Amylin Lawsuit
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/27/2015)...  The fairness of the proposed acquisition of Thoratec ... ("St. Jude") is the subject of an investigation by ... firm.  The investigation is focusing on possible breaches of ... Board of Directors of THOR for agreeing to sell ... Company announced it had reached a definitive agreement for ...
    (Date:7/27/2015)... BOULDER, Colo. , July 27, 2015 ... will report financial results for the fourth ... and hold a conference call to discuss ... Ron Squarer, Chief Executive Officer will lead ... 2015Time:9:00 a.m. Eastern TimeToll-Free:(844) 464-3927Toll:(765) 507-2598Pass Code: ...
    (Date:7/27/2015)... As per the new market report ... Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2021," ... 2014, growing at a CAGR of 13.2% from 2015 to ... The global bionics market is growing primarily due to ... to paralysis or amputation of body parts. In addition, increasing ...
    Breaking Medicine Technology:WeissLaw LLP: Thoratec Corporation Acquisition By St. Jude Medical May Not Be In The Best Interest Of THOR Shareholders 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 4
    ... SCHAUMBURG, Ill., Sept. 30 Sagent Pharmaceuticals, Inc., ... that it has launched vinorelbine injection, USP, an ... of vinorelbine injection, USP in the United States ... shipping vinorelbine injection immediately. , "Sagent has launched ...
    ... ROCKLAND, Mass., Sept. 30 EMD Serono, ... today the submission of a New Drug Application (NDA) ... Cladribine Tablets, EMD Serono,s proprietary investigational oral formulation of ... with relapsing forms of multiple sclerosis (MS). Cladribine Tablets ...
    Cached Medicine Technology:Sagent Pharmaceuticals Launches Vinorelbine Injection, USP 2EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States 2EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States 3EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States 4
    (Date:7/27/2015)... Lexington, Kentucky (PRWEB) , ... July 28, 2015 ... ... KORT (Kentucky Orthopedic Rehab Team) as the sports medicine provider for the entire ... (ACHS). , According to ACHS Athletic Director Rick Sallee, “Student safety and ...
    (Date:7/27/2015)... ... July 28, 2015 , ... The National Association ... 2015 Professional Woman of the Year. Ms. Baum-Lappe is recognized with this prestigious ... women in the country, spanning virtually every industry and profession, the National Association ...
    (Date:7/27/2015)... ... 27, 2015 , ... In a piece published July 22 on ... surgery and explained why people should not shy away from their own personal aspirations. ... the few and celebrate it for the modern wonder that it is.” This is ...
    (Date:7/27/2015)... ... ... The Maricopa Community Colleges today announced a new program that ... into and complete college. , The “Bridging Success Initiative,” funded by the ... from across the valley. , The initiative advisory board has representatives from Arizona State ...
    (Date:7/27/2015)... ... July 27, 2015 , ... In an ... hiking to its options. Already an industry leader because of its use ... lookout for the latest successful trends in helping people to overcome addiction and ...
    Breaking Medicine News(10 mins):Health News:KORT Physical Therapy Named Sports Medicine Provider for Anderson County School System 2Health News:KORT Physical Therapy Named Sports Medicine Provider for Anderson County School System 3Health News:NAPW Inducts Gilda Baum-Lappe, Journalist / Correspondent of Hollywood Foreign Press Association Into its VIP Woman of the Year Circle 2Health News:Recent Op-Ed Defending Plastic Surgery Highlights the Personal Side of Cosmetic Procedures, says Beverly Hills Physicians 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 2Health News:Maricopa Community Colleges Launch Program To Help Youth In Foster Care Finish College 3Health News:Hiking Adds Benefits to Recovery at Serenity Palms 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 3
    ... new class of drugs based on a widely used ... the laboratory and in mice, according to researchers. The ... treatment of these tumors. // ,Previous drugs ... same cell targets as hydroxyurea, but had serious side ...
    ... mantra of the media as dozens of people exposed to ... potent antibiotic. But if the supply dwindles, doctors say other ... previous generation's wonder drug: penicillin. Although alternatives exist, Cipro is ... , // ,It helped that Cipro was the ...
    ... An experimental anti-cancer drug has shown effectiveness in treating ... report. Researchers say the drug probably acts on many ... for treating other types of cancer. Dr. Antonio Fojo ... colleagues tested the drug, depsipeptide//, in patients with T-cell ...
    ... virus that kills at least 30 percent of its ... the globe more than two decades ago. Scientists retained ... and stored them in secure laboratories in Atlanta, Georgia, ... of many potential bioterrorism threats, but "perhaps it is ...
    ... warned doctors that doxycycline -- an antibiotic being prescribed ... -- can stunt fetal growth when taken by pregnant ... urged doctors to prescribe Cipro to pregnant women. The ... being overprescribed in the general population, possibly causing common ...
    ... drugs, statements about drug benefits are often overblown ... expected benefit; instead, they make an emotional appeal," ... New Hampshire. // ,Instead of telling ... medicine is going to prevent some outcome, these ...
    Cached Medicine News:
    ... EXPRESS Seeding Cartridge System is a single-use, ... seeds and spacers into a Bard BrachyStar ... has a(n): outer radiation safety shield, inner ... spacers, integrally molded fitting that connects the ...
    ... Luna is a very easy to use ... in close co-operation with practising urologists as ... lower urinary tract dysfunctions. The system offers ... and flow during a natural bladder filling, ...
    A compact mobile System Cart gives mobility within your department. The cart accomodates the Uromac Median data processor, desktop computer, printer and provides stowage space. Patient related transd...
    ... Dorado™ will exceed your expectations with ... flexible enough to be customized to meet ... your needs grow, Dorado™ can be upgraded ... such as video and database management, it ...
    Medicine Products: